These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 4809201)

  • 21. Heterogeneity on familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride-cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate.
    Davignon J; Aubry F; Noël C; Lapierre Y; Lafortune M
    Rev Can Biol; 1971 Dec; 30(4):307-18. PubMed ID: 5135408
    [No Abstract]   [Full Text] [Related]  

  • 22. [The treatment of essential hyperlipidemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of clofibrate on arginine-induced insulin and glucagon secretion.
    Eaton RP
    Metabolism; 1973 Jun; 22(6):763-7. PubMed ID: 4350845
    [No Abstract]   [Full Text] [Related]  

  • 24. [Lipoproteins, glucose tolerance and insulin secretion].
    Debry G; Mejean L; Drouin P; Villaume C; Pointel JP; Vernhes G
    Ann Nutr Aliment; 1979; 33(1):113-34. PubMed ID: 382956
    [No Abstract]   [Full Text] [Related]  

  • 25. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
    Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
    Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types 3, IV, and V familial hyperlipoproteinemia.
    Glueck CJ
    Metabolism; 1971 Jul; 20(7):691-702. PubMed ID: 5090133
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of clofibrate on glucide tolerance in patients with ischemic heart disease and hyperlipoproteinemia].
    Bornemisza P; Csögör I
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1978; 30(6):543-6. PubMed ID: 34860
    [No Abstract]   [Full Text] [Related]  

  • 28. Norethindrone acetate, postheparin lipolytic activity, and plasma triglycerides in familial types I, 3, IV, and V hyperlipoproteinemia. Studies in 26 patients and 5 normal persons.
    Glueck CJ; Levy RI; Fredrickson DS
    Ann Intern Med; 1971 Sep; 75(3):345-52. PubMed ID: 5568147
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
    Ferrari C; Testori GP; Bertazzoni A; Romussi M; Caldara R; Frezzati S
    Horm Metab Res; 1978 Jan; 10(1):4-6. PubMed ID: 631736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma lipoproteins, glucose tolerance and insulin response in primary gout.
    Wiedemann E; Rose HG; Schwartz E
    Am J Med; 1972 Sep; 53(3):299-307. PubMed ID: 5054722
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipoproteins and the relative importance of plasma cholesterol and triglycerides in peripheral arterial disease.
    Newall RG; Bliss BP
    Angiology; 1973 May; 24(5):297-302. PubMed ID: 4350611
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.
    Calvert GD; Blight L; Franklin J; Oliver J; Wise P; Gallus AS
    Eur J Clin Pharmacol; 1980 May; 17(5):355-62. PubMed ID: 6998709
    [No Abstract]   [Full Text] [Related]  

  • 33. Glucose kinetics and fatty acids in dogs on matched insulin infusion after glucose load.
    Vranic M; Fono P; Kovacevic N; Lin BJ
    Metabolism; 1971 Oct; 20(10):954-67. PubMed ID: 5097683
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clofibrate and carbohydrate metabolism: behavior of blood insulin in patients with blood lipid disorders].
    Ceruso D; Frisina N; Nicita-Mauro V
    Boll Soc Ital Cardiol; 1975; 20(11):1439-47. PubMed ID: 1234442
    [No Abstract]   [Full Text] [Related]  

  • 35. [Influence of fat or carbohydrate rich diet on the serum lipoprotein pattern of a child with primary hypertriglyceridemia (type V hyperlipoproteinemia according to Frederickson) (author's transl)].
    Müller WD; Kostner GM
    Wien Klin Wochenschr; 1974 Dec; 86(24):757-62. PubMed ID: 4439935
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
    Enger SC; Johnsen V; Samuelsen A; Laws EA
    Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Serum beta-lipoprotein curve in type II and IV hyperlipoproteinemia after glucose loading].
    Plamieniak Z; Amalowicz B; Liebhart J
    Pol Tyg Lek; 1972 Jan; 27(1):13-5. PubMed ID: 5060023
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of clofibrate on glucose tolerance in maturity onset diabetes.
    Barnett D; Craig JG; Robinson DS; Rogers MP
    Br J Clin Pharmacol; 1977 Aug; 4(4):455-8. PubMed ID: 901737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial type IV hyperlipoproteinemia.
    Schreibman PH; Wilson DE; Arky RA
    N Engl J Med; 1969 Oct; 281(18):981-5. PubMed ID: 5824739
    [No Abstract]   [Full Text] [Related]  

  • 40. [Influence of caffein on the daily profile of metabolites from lipid and carbohydrate metabolism as well as of insulin secretion].
    Siedek H; Hammerl H; Henk W; Köhn HD; Kränzl C; Nebosis G; Pichler O; Studlar M
    Verh Dtsch Ges Inn Med; 1971; 77():606-10. PubMed ID: 5155907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.